GLAXF - Liquidia IPO: Phase 3 Clinical Stage That Interested The Bill Gates Foundation
With remarkable investors like the foundation of Bill Gates, agreements with GlaxoSmithKline Plc (GLAXF) and a total addressable market of more than $4 billion, Liquidia Technologies, Inc. (LQDA) seems like a must-follow stock. Furthermore, Liquidia’s product candidate LIQ861 is at Phase 3, and data will be delivered in the first half of 2019. If the FDA approves the commercialization of the product, the stock price could run.
Source: Prospectus
Business Overview
Founded in 2014, Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company developing and commercializing products for the treatment of pulmonary arterial